Rethinking Menopause Hormone Therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Rethinking Menopause Hormone Therapy

A JAMA Perspective outlines how updated FDA labeling may reshape menopause care.

  • By

  • Kerri Miller

  • April 23, 2026

  • 3 min

Share

  • 1

    Menopausal hormone therapy (MHT) use declined from over 20% to under 5% after the Women’s Health Initiative.

  • 2

    The FDA's removal of black box warnings on MHT presents an opportunity for improved patient care.

  • 3

    Research shows that initiating MHT before age 60 or within 10 years of menopause has a favorable benefit-risk profile.

  • 4

    There are significant gaps in menopause education and symptom screening among clinicians treating middle-aged women.

  • 5

    The FDA label change emphasizes the need for routine symptom assessment and individualized discussions about MHT.

Original Source(s)

Rethinking Menopause Hormone Therapy

  • by Kerri Miller

  • April 23, 2026

Related Content

Vaginal DNA Assay Shows Promise

A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.

Women’s Engagement With Different Internet-Enabled Technologies to Access Digital Menopause Information: Mixed Methods, Multiphase Sequential Study

An examination into the safety and efficacy of Khapregesic®, a Khaya senegalensis preparation, on physical and psychological wellbeing in women experiencing menopausal symptoms: a randomised, double-blind, placebo-controlled trial